 Ashley Nassiri
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cochlear Implantation | 24 | 2025 | 82 | 10.000 |
Why?
| | Cochlear Implants | 22 | 2025 | 95 | 8.520 |
Why?
| | Speech Perception | 12 | 2025 | 91 | 5.160 |
Why?
| | Neuroma, Acoustic | 16 | 2024 | 55 | 3.730 |
Why?
| | Hearing Loss, Sensorineural | 9 | 2023 | 73 | 3.590 |
Why?
| | Hearing | 6 | 2025 | 132 | 2.610 |
Why?
| | Stapes Surgery | 5 | 2023 | 10 | 2.180 |
Why?
| | Hearing Loss | 6 | 2025 | 247 | 2.150 |
Why?
| | Deafness | 4 | 2022 | 78 | 1.620 |
Why?
| | Otolaryngology | 4 | 2025 | 108 | 1.410 |
Why?
| | Patient Satisfaction | 4 | 2025 | 705 | 1.180 |
Why?
| | Treatment Outcome | 17 | 2025 | 11695 | 1.140 |
Why?
| | Endoscopy | 4 | 2020 | 316 | 1.090 |
Why?
| | Radiosurgery | 4 | 2024 | 401 | 0.970 |
Why?
| | Hearing Tests | 3 | 2025 | 51 | 0.920 |
Why?
| | Facial Nerve | 5 | 2023 | 39 | 0.910 |
Why?
| | Cholesteatoma, Middle Ear | 1 | 2024 | 4 | 0.870 |
Why?
| | Mastoidectomy | 1 | 2024 | 5 | 0.860 |
Why?
| | Ear Canal | 1 | 2024 | 15 | 0.860 |
Why?
| | Hearing Loss, Conductive | 2 | 2021 | 24 | 0.820 |
Why?
| | Cholesteatoma | 1 | 2023 | 10 | 0.800 |
Why?
| | Telemedicine | 5 | 2025 | 948 | 0.780 |
Why?
| | Stapedius | 2 | 2022 | 2 | 0.740 |
Why?
| | Otosclerosis | 2 | 2019 | 5 | 0.730 |
Why?
| | Hearing Loss, Central | 2 | 2019 | 6 | 0.720 |
Why?
| | Retrospective Studies | 25 | 2025 | 17101 | 0.700 |
Why?
| | Tendons | 2 | 2023 | 129 | 0.670 |
Why?
| | Surgical Equipment | 1 | 2020 | 9 | 0.640 |
Why?
| | Value-Based Purchasing | 1 | 2020 | 8 | 0.640 |
Why?
| | Nasal Surgical Procedures | 1 | 2020 | 6 | 0.630 |
Why?
| | Nasal Obstruction | 1 | 2020 | 26 | 0.620 |
Why?
| | Humans | 63 | 2025 | 144957 | 0.600 |
Why?
| | Adult | 24 | 2025 | 40506 | 0.590 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 220 | 0.590 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2019 | 32 | 0.580 |
Why?
| | Gingival Neoplasms | 1 | 2019 | 10 | 0.580 |
Why?
| | Labyrinthitis | 1 | 2018 | 3 | 0.580 |
Why?
| | Mandibular Neoplasms | 1 | 2019 | 22 | 0.580 |
Why?
| | Otologic Surgical Procedures | 1 | 2018 | 25 | 0.560 |
Why?
| | Hearing Aids | 4 | 2025 | 93 | 0.550 |
Why?
| | Evoked Potentials, Auditory | 1 | 2019 | 180 | 0.550 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1099 | 0.510 |
Why?
| | Reoperation | 2 | 2020 | 631 | 0.490 |
Why?
| | Neurilemmoma | 3 | 2024 | 25 | 0.450 |
Why?
| | Postoperative Period | 4 | 2020 | 354 | 0.450 |
Why?
| | Ear, Inner | 2 | 2024 | 51 | 0.420 |
Why?
| | Bone Conduction | 3 | 2023 | 24 | 0.420 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 642 | 0.400 |
Why?
| | Postoperative Complications | 5 | 2023 | 2920 | 0.390 |
Why?
| | Hearing Loss, Bilateral | 2 | 2023 | 11 | 0.380 |
Why?
| | Decision Making | 1 | 2020 | 980 | 0.370 |
Why?
| | Microsurgery | 3 | 2022 | 72 | 0.360 |
Why?
| | Aged | 13 | 2025 | 25947 | 0.360 |
Why?
| | Male | 21 | 2025 | 72406 | 0.360 |
Why?
| | Prospective Studies | 6 | 2025 | 7997 | 0.350 |
Why?
| | Incidence | 4 | 2023 | 2883 | 0.350 |
Why?
| | Middle Aged | 15 | 2025 | 35928 | 0.340 |
Why?
| | Female | 20 | 2025 | 78376 | 0.340 |
Why?
| | Tinnitus | 2 | 2022 | 68 | 0.330 |
Why?
| | Preoperative Period | 2 | 2020 | 149 | 0.290 |
Why?
| | Surgeons | 2 | 2025 | 340 | 0.290 |
Why?
| | United States | 9 | 2025 | 15988 | 0.270 |
Why?
| | Ear Neoplasms | 2 | 2024 | 10 | 0.270 |
Why?
| | Marketing | 1 | 2025 | 24 | 0.230 |
Why?
| | Incus | 2 | 2023 | 6 | 0.230 |
Why?
| | Stapes | 2 | 2023 | 25 | 0.230 |
Why?
| | Nonprescription Drugs | 1 | 2025 | 65 | 0.220 |
Why?
| | Mastoid | 1 | 2024 | 12 | 0.220 |
Why?
| | Facial Paralysis | 1 | 2023 | 23 | 0.200 |
Why?
| | Child | 7 | 2023 | 22657 | 0.200 |
Why?
| | Artifacts | 1 | 2023 | 139 | 0.190 |
Why?
| | Cranial Nerve Neoplasms | 1 | 2022 | 7 | 0.190 |
Why?
| | Neoplasms, Connective Tissue | 1 | 2022 | 3 | 0.190 |
Why?
| | Osteomalacia | 1 | 2022 | 3 | 0.190 |
Why?
| | Mesenchymoma | 1 | 2022 | 10 | 0.180 |
Why?
| | Paraneoplastic Syndromes | 1 | 2022 | 12 | 0.180 |
Why?
| | Cadaver | 1 | 2023 | 304 | 0.180 |
Why?
| | Child, Preschool | 4 | 2023 | 11799 | 0.180 |
Why?
| | Hemangioma, Capillary | 1 | 2021 | 14 | 0.180 |
Why?
| | Prolapse | 1 | 2021 | 6 | 0.170 |
Why?
| | Facial Nerve Diseases | 1 | 2021 | 8 | 0.170 |
Why?
| | Nutrition Surveys | 1 | 2023 | 282 | 0.170 |
Why?
| | Meningioma | 1 | 2022 | 87 | 0.170 |
Why?
| | Meningeal Neoplasms | 1 | 2022 | 94 | 0.170 |
Why?
| | Intraoperative Period | 1 | 2021 | 69 | 0.170 |
Why?
| | Cartilage Diseases | 1 | 2022 | 45 | 0.170 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2021 | 108 | 0.170 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 189 | 0.170 |
Why?
| | Paraganglioma | 1 | 2021 | 65 | 0.160 |
Why?
| | Travel | 1 | 2022 | 136 | 0.160 |
Why?
| | Benchmarking | 1 | 2022 | 188 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 5 | 2023 | 3869 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2022 | 8279 | 0.160 |
Why?
| | Young Adult | 4 | 2022 | 14126 | 0.150 |
Why?
| | Quality of Life | 4 | 2025 | 3192 | 0.150 |
Why?
| | Appointments and Schedules | 1 | 2020 | 97 | 0.150 |
Why?
| | Ear Ossicles | 1 | 2019 | 11 | 0.150 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5872 | 0.150 |
Why?
| | Audiometry | 1 | 2019 | 35 | 0.140 |
Why?
| | Patient Advocacy | 1 | 2019 | 74 | 0.140 |
Why?
| | Feedback | 1 | 2019 | 181 | 0.140 |
Why?
| | Temporal Bone | 3 | 2022 | 45 | 0.130 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 509 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2023 | 2738 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 769 | 0.130 |
Why?
| | Rural Population | 1 | 2022 | 650 | 0.120 |
Why?
| | Tumor Burden | 3 | 2022 | 322 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 489 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2020 | 544 | 0.110 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1465 | 0.110 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2014 | 22 | 0.110 |
Why?
| | Skin Neoplasms | 1 | 2022 | 847 | 0.110 |
Why?
| | Haploinsufficiency | 1 | 2014 | 55 | 0.100 |
Why?
| | Infant | 2 | 2018 | 10039 | 0.100 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.100 |
Why?
| | Adolescent | 4 | 2022 | 22453 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2020 | 853 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.090 |
Why?
| | Communication | 1 | 2019 | 967 | 0.090 |
Why?
| | Cochlea | 2 | 2023 | 73 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2014 | 321 | 0.090 |
Why?
| | Brain Neoplasms | 1 | 2021 | 1322 | 0.090 |
Why?
| | DNA Damage | 1 | 2014 | 430 | 0.090 |
Why?
| | Neurosurgical Procedures | 2 | 2023 | 202 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1358 | 0.080 |
Why?
| | Pandemics | 3 | 2022 | 1695 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2584 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6053 | 0.060 |
Why?
| | Pain | 2 | 2022 | 782 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2025 | 205 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3415 | 0.050 |
Why?
| | Skull Base | 1 | 2023 | 54 | 0.050 |
Why?
| | Dissection | 1 | 2023 | 56 | 0.050 |
Why?
| | Neoplasm Regression, Spontaneous | 1 | 2022 | 3 | 0.050 |
Why?
| | Petrous Bone | 1 | 2022 | 8 | 0.050 |
Why?
| | Audiometry, Evoked Response | 1 | 2022 | 15 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2024 | 255 | 0.050 |
Why?
| | Head | 1 | 2023 | 120 | 0.050 |
Why?
| | Cochlear Nerve | 1 | 2022 | 7 | 0.050 |
Why?
| | Auditory Threshold | 1 | 2022 | 51 | 0.050 |
Why?
| | Electrodes, Implanted | 1 | 2023 | 115 | 0.050 |
Why?
| | Magnets | 1 | 2022 | 21 | 0.050 |
Why?
| | Ear Cartilage | 1 | 2022 | 4 | 0.050 |
Why?
| | Face | 1 | 2023 | 174 | 0.050 |
Why?
| | Literacy | 1 | 2022 | 13 | 0.040 |
Why?
| | Ear, External | 1 | 2022 | 21 | 0.040 |
Why?
| | Scalp | 1 | 2022 | 37 | 0.040 |
Why?
| | Chorda Tympani Nerve | 1 | 2021 | 17 | 0.040 |
Why?
| | Craniotomy | 1 | 2022 | 82 | 0.040 |
Why?
| | Round Window, Ear | 1 | 2021 | 18 | 0.040 |
Why?
| | Reflex | 1 | 2022 | 69 | 0.040 |
Why?
| | Cranial Nerves | 1 | 2020 | 12 | 0.040 |
Why?
| | Ligaments | 1 | 2021 | 75 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 408 | 0.040 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2020 | 71 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5965 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2023 | 1325 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2020 | 128 | 0.040 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 562 | 0.030 |
Why?
| | Medicare | 1 | 2022 | 887 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1141 | 0.030 |
Why?
| | Alkylation | 1 | 2014 | 27 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2852 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2014 | 87 | 0.030 |
Why?
| | Heterozygote | 1 | 2014 | 315 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2021 | 2947 | 0.020 |
Why?
| | Cell Death | 1 | 2014 | 383 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 919 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2022 | 5417 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2385 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 627 | 0.020 |
Why?
| | Time Factors | 1 | 2022 | 7183 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1915 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2880 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 2832 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5997 | 0.010 |
Why?
| | Mice | 1 | 2014 | 18365 | 0.010 |
Why?
| | Animals | 1 | 2014 | 38109 | 0.010 |
Why?
|
|
Nassiri's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|